Gynaecologic cancers

Gynecologic cancers are cancers that start in a woman's reproductive organs. The term covers five main groups: cancers of the cervix, the uterus (endometrium), the ovaries, the vagina and the vulva. Although they are grouped together because of where they begin, they are genuinely different diseases - each with its own causes, warning signs, methods of detection and treatment pathways.

This guide focuses on the three most common types - cervical, endometrial (uterine) and ovarian cancer - and touches briefly on vulvar and vaginal cancers, which are rarer. Understanding which organ is involved matters, because it shapes everything from whether a screening test exists to how the cancer is staged and treated.

The encouraging reality is that some gynecologic cancers, particularly cervical cancer, are highly preventable, and many gynecologic cancers can be treated effectively when found early. Whatever the diagnosis, decisions are best made with a multidisciplinary gynecologic oncology team rather than alone. Nothing in this article is a substitute for advice from your own doctors, who can assess your individual situation.

Each gynecologic cancer has its own subtypes, which influence treatment and outlook.

Cervical cancer arises in the cervix, the lower part of the uterus that connects to the vagina. The two main histological types are squamous cell carcinoma (the majority of cases, beginning in the flat cells lining the outer cervix) and adenocarcinoma (beginning in the glandular cells). Less common types also occur.

Endometrial (uterine) cancer begins in the lining of the uterus, the endometrium. Most cases are endometrioid adenocarcinoma. Less common, more aggressive subtypes include serous and clear cell carcinoma. A separate, rarer group called uterine sarcomas develops in the muscle or supporting tissue of the uterus rather than the lining, and is managed differently.

Ovarian cancer is dominated by epithelial ovarian carcinoma. The American Cancer Society reports that about 85% to 90% of ovarian cancers are epithelial, with high-grade serous carcinoma a common form. Less common types include germ cell tumours (often in younger women, and the ACS notes these generally have a favourable outlook) and sex cord-stromal tumours. Importantly, the ACS notes that fallopian tube cancer and primary peritoneal cancer are usually treated in a way similar to epithelial ovarian cancer.

Vulvar and vaginal cancers are uncommon. Many are squamous cell carcinomas, and a substantial share are linked to human papillomavirus (HPV).

Risk factors differ markedly between the three main cancers, which is part of why they are considered separate diseases.

Cervical cancer is caused, in nearly all cases, by persistent infection with high-risk types of HPV. The National Cancer Institute states that virtually all cervical cancer is caused by HPV, and that types HPV 16 and HPV 18 are responsible for most HPV-related cancers. Factors that can increase the chance of a long-lasting HPV infection include smoking, a weakened immune system (including HIV) and not being screened.

Endometrial cancer is strongly linked to prolonged exposure of the uterine lining to oestrogen unopposed by progesterone. Recognised risk factors include increasing age (most cases occur after menopause), obesity, diabetes, certain reproductive and menstrual histories, some hormone therapies, tamoxifen treatment, and inherited conditions such as Lynch syndrome.

Ovarian cancer risk rises with age and family history. Inherited mutations in the BRCA1 and BRCA2 genes, and Lynch syndrome, can meaningfully raise risk. Other factors include certain reproductive histories. Having a risk factor does not mean cancer will develop, and many people with cancer have no identifiable risk factor.

Symptoms vary by cancer type, and early-stage disease may cause none at all - which is why screening (where it exists) matters.

Cervical cancer in its early stages often has no symptoms. Later signs can include bleeding between periods, after sex or after menopause, unusual vaginal discharge, and pelvic pain.

Endometrial (uterine) cancer symptoms most often appear as abnormal bleeding - particularly any bleeding after menopause, or heavy or irregular bleeding before menopause. Because this symptom tends to appear relatively early, many uterine cancers are found at an early, treatable stage. Pelvic pain or unusual discharge can also occur.

Ovarian cancer is more difficult because symptoms are often vague and easy to attribute to other causes. The American Cancer Society highlights bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary urgency or frequency as the most common symptoms. The ACS notes that, when due to ovarian cancer, these tend to be persistent and a clear change from normal.

When to see a doctor: any bleeding after menopause, persistent abnormal bleeding, or new symptoms that persist deserve prompt medical assessment. These symptoms are far more often caused by benign conditions, but checking is sensible, and early evaluation can help.

Screening availability differs sharply between these cancers - a crucial distinction.

Cervical cancer can often be detected early through screening. The Pap test and HPV testing can find precancerous changes in the cervix before cancer develops, allowing them to be treated. The World Health Organization recommends screening with a high-performance HPV test every 5-10 years starting at age 30 (earlier, from age 25, for women living with HIV), and notes that self-collected HPV samples have been shown to be as reliable as those collected by a clinician. Combined with HPV vaccination - which the NCI estimates can prevent up to 90% of cancers caused by HPV infection and is recommended around ages 11-12 - cervical cancer is considered largely preventable. WHO's global elimination strategy sets 90-70-90 targets for vaccination, screening and treatment by 2030.

Ovarian cancer has no reliable screening test for women at average risk; available tests are not accurate enough to find it early in most women, and many ovarian cancers are found at a later stage. Women with a strong family history or known BRCA or Lynch syndrome mutations should discuss genetic counselling and risk-reduction options with a specialist.

Endometrial cancer has no routine screening for average-risk women - the NCI states there is no standard or routine screening test - but because it usually causes early bleeding, prompt evaluation of abnormal bleeding can support earlier detection. The NCI notes that women with Lynch syndrome may be offered additional surveillance, such as yearly transvaginal ultrasound.

Diagnosis combines clinical examination, imaging and - decisively - a tissue biopsy, since only examining cells under a microscope confirms cancer and its subtype.

For cervical cancer, an abnormal Pap or HPV test is typically followed by colposcopy and biopsy. For endometrial cancer, an endometrial biopsy or a procedure called dilation and curettage samples the uterine lining; transvaginal ultrasound helps assess the lining's thickness. For ovarian cancer, evaluation may include pelvic ultrasound, CT or MRI imaging and blood tumour markers such as CA-125, though diagnosis is often confirmed at the time of surgery.

All three are staged using the FIGO system (International Federation of Gynecology and Obstetrics), often alongside the AJCC TNM system, describing how far the cancer has spread. In broad terms: Stage I is confined to the organ of origin; Stage II involves nearby structures; Stage III involves regional lymph nodes or pelvic/abdominal spread; and Stage IV indicates spread to distant organs. For cervical cancer, the NCI describes Stage I as found in the cervix only, with later stages reflecting spread to the vagina, tissue around the uterus, the pelvic wall, lymph nodes, the bladder or rectum, and distant sites. Tumour grade - how abnormal the cells look - also guides treatment, especially in uterine cancer. Accurate staging is the foundation of every treatment plan.

Treatment is tailored to the cancer type, stage, grade, your general health and your wishes, and is best coordinated by a multidisciplinary tumour board - gynecologic oncologists, medical and radiation oncologists, pathologists and radiologists planning care together. The main modalities are used alone or in combination.

Surgery is central to most gynecologic cancers. For early cervical and uterine cancers this may involve removing the uterus (hysterectomy) and sometimes surrounding tissue and lymph nodes; in selected early cases, fertility-sparing options may be possible. For ovarian cancer, the NCI describes cytoreductive (debulking) surgery - which may include hysterectomy, removal of both ovaries and tubes, and omentectomy - to remove as much tumour as possible.

Radiation therapy (external beam and/or internal brachytherapy) is widely used in cervical cancer, often combined with chemotherapy, and in some uterine cancers.

Chemotherapy, frequently platinum-based combinations, is a mainstay for ovarian cancer and is used in advanced cervical and uterine disease.

Targeted therapy and immunotherapy are increasingly important. The NCI notes the use of PARP inhibitors (a drug class given as maintenance, particularly relevant for some BRCA-related ovarian cancers), anti-angiogenic drugs that limit a tumour's blood supply, and immune checkpoint inhibitors for certain cervical and uterine cancers. Drug classes are named here as neutral examples; the right choice depends on tumour biology and molecular testing your oncologist will discuss with you.

The statistics below are population-level estimates, strongly dependent on stage at diagnosis. They describe groups of people diagnosed years ago and are not a prediction for any individual. Your own outlook depends on many factors - the specific subtype and grade, your age and overall health, molecular features and how the cancer responds to treatment. Treatments also continue to evolve over time. Please discuss your situation with your oncologist.

Cervical cancer (Cancer Research UK, England, diagnosed 2013-2017): around 95% of people survive 5 years or more at Stage 1, almost 70% at Stage 2, more than 40% at Stage 3, and around 15% at Stage 4.

Endometrial (uterine) cancer (American Cancer Society, SEER, diagnosed 2015-2021): 5-year relative survival is about 96% for localized disease, 72% for regional, 22% for distant, and about 84% across all stages combined.

Ovarian cancer (American Cancer Society, SEER, invasive epithelial ovarian cancer, diagnosed 2015-2021): 5-year relative survival is about 92% for localized disease, 71% for regional and 32% for distant, with about 51% across all stages combined - figures that are lower in part because it is often found at a later stage.

Care extends well beyond active treatment. Supportive (palliative) care - which can be provided at any stage, alongside treatment aimed at controlling or curing the cancer - focuses on relieving symptoms such as pain, nausea and fatigue, and on emotional, sexual and psychological wellbeing. It is appropriate from diagnosis onward, not only in advanced disease.

Treatments for gynecologic cancers can have lasting effects, including changes to fertility, early menopause, lymphoedema (swelling) after lymph node surgery, and sexual health concerns. Raising these openly with your team allows for practical support - from fertility preservation discussions before treatment to physiotherapy, hormone advice and counselling.

Follow-up care after treatment typically involves scheduled examinations and, where appropriate, imaging or tumour-marker tests to watch for recurrence and manage side effects. Your team will set a personalised follow-up schedule. Nutrition, physical activity, smoking cessation and emotional support all contribute to recovery and long-term quality of life, and many centres offer survivorship programmes to coordinate this care.

Some patients consider treatment abroad to access experienced gynecologic-oncology centres or to shorten waiting times. If you are exploring this, careful preparation makes the process safer and smoother.

Several factors influence the overall scope of care, which is why no single plan applies to everyone: the specific cancer type and stage; the combination of treatments required (surgery, radiotherapy, chemotherapy, targeted or immunotherapy); the length of hospital stay; the need for molecular and genetic testing; imaging and laboratory work; supportive care; and the duration of follow-up. Because plans are highly individual, the responsible approach is to request a personalised assessment after a specialist has reviewed your records.

To prepare, gather and organise your medical records: pathology and biopsy reports (and, ideally, the original tissue blocks or slides for review), imaging scans on disc, blood and tumour-marker results, a summary of treatments already received, and a current medication list. Having these translated and ready allows an overseas tumour board to give accurate, specific advice. BergemHealth, as a medical-tourism concierge, can help coordinate records, scheduling and logistics so your focus stays on care. Begin any plan by consulting a qualified oncologist about whether and where treatment abroad is appropriate for you.

Turkiye (Turkey) is one of several destinations patients consider for cancer care, with internationally accredited hospitals, experienced gynecologic-oncology teams and modern surgical, radiotherapy and imaging facilities, often combined with integrated support for international patients. As with anywhere, quality varies between centres, so the decision should rest on objective criteria rather than reputation alone.

When evaluating any cancer centre - in Turkiye or elsewhere - it is reasonable to verify the following: that care is delivered by a genuine multidisciplinary tumour board covering gynecologic, medical and radiation oncology, pathology and radiology; the centre's accreditation (for example internationally recognised quality accreditation); the experience and qualifications of the treating surgeons and oncologists in your specific cancer; the availability of modern radiotherapy, molecular pathology and targeted/immunotherapy options; and clear arrangements for follow-up, complication management and communication with your doctors at home.

Ask how treatment recommendations are reached, whether your case will be formally reviewed by the tumour board, and how a second opinion fits in. A trustworthy centre will welcome these questions and provide transparent, written answers. A concierge such as BergemHealth can help you compare accredited options and arrange consultations, but the clinical decision should always be made with qualified oncologists.

Clinical trials study new treatments or new ways of using existing ones and may offer access to therapies not yet widely available. They are a legitimate, carefully regulated option for some patients at various stages of disease. National cancer authorities such as the NCI maintain searchable registries of trials, and your oncologist can advise whether any are suitable and where they are running, including internationally.

Seeking a second opinion is a normal and constructive part of cancer care, not a sign of distrust. Because gynecologic cancers are diverse and treatment is evolving, having your pathology slides and imaging reviewed by another specialist team - including at an experienced centre abroad - can help confirm the diagnosis, clarify staging and ensure the full range of options is considered. Many clinicians support this, and it can bring real peace of mind.

Throughout, keep a qualified oncologist or multidisciplinary team at the centre of your decisions. Reliable information, an accredited centre, an honest second opinion and clear answers to your questions together form a strong foundation for choosing the path that is right for you.